Merck KGAA Taps PDS For Cancer Vaccine Technology
This article was originally published in The Pink Sheet Daily
Executive Summary
The German pharma signs a deal with Indiana-based PDS Biotechnology that will use the company’s adjuvant technology to boost its own compounds.
You may also be interested in...
Merck KGaA Changes Manager Incentives, But Stays Mum On Job Losses
Germany's Merck KGaA implements share-based incentive scheme for top management and vows to improve financial transparency, while discussing cost-savings with employees.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.